Quarterly report pursuant to Section 13 or 15(d)

STOCK OPTIONS AND WARRANTS

v3.24.3
STOCK OPTIONS AND WARRANTS
3 Months Ended
Jul. 31, 2024
Share-Based Payment Arrangement [Abstract]  
STOCK OPTIONS AND WARRANTS

NOTE 5 – STOCK OPTIONS AND WARRANTS

 

2022 Equity Incentive Plan

 

Effective December 28, 2022, the Company implemented the 2022 Equity Incentive Plan (“2022 Equity Plan”) as approved by the Company’s stockholders. The 2022 Equity Plan is administered by the Compensation Committee of the Board and has 2,750,000 shares available under this plan. The 2022 Equity Plan can issue various types of awards, as follows: stock options, stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. The 2022 Equity Plan is available to be issued to employees, directors, consultants, and other individuals who provide services to the Company. An incentive stock options (“ISOs”) can only be granted to employees and shall not exceed 10-years (5-years in the case of ISOs granted to any 10% shareholder).

 

Stock Options

 

As of July 31, 2024, the Company had 924,830 outstanding stock options to its directors and officers (collectively, “Employee Options”) and consultants (“Non-Employee Options”).

 

During the three months ended July 31, 2024, and 2023, the Company granted no Employee Options.

 

During the three months ended July 31, 2024 and 2023, the Company granted no Non-Employee Options.

 

A summary of the Company’s stock option activity and related information for the three months ended July 31, 2024, are shown below:

                 
Options   Number of Options     Weighted Average Exercise Price per Share  
Outstanding, April 30, 2024     925,164     $ 2.97  
Issued            
Expired     (333 )     55.50  
Outstanding, July 31, 2024     924,830     $ 2.95  
Exercisable, July 31, 2024     645,291     $ 3.23  
Vested and expected to vest     924,830     $ 2.95  

 

A summary of the activity for unvested stock options during the three months ended July 31, 2024 is as follows: 

               
    Options     Weighted
Average
Grant Date
Fair Value
Per Share
 
Unvested, April 30, 2024     279,536       1.70  
Granted            
Vested            
Forfeited            
Unvested, July 31, 2024     279,536     $ 1.70  

 

The Company recorded $222,677 and $0 of stock-based compensation related to the issuance of Employee Options to certain officers and directors in exchange for services during the three months ended July 31, 2024, and 2023, respectively. At July 31, 2024, there remained $252,015 of unrecognized compensation expense related to unvested Employee Options granted to officers and directors.

 

The aggregate intrinsic value of outstanding options as of July 31, 2024 was $0. This represents options with exercise prices less than the $1.96 per share closing price of the Company’s common stock on July 31, 2024.

  

Warrants

 

Pursuant to the Private Placement (as defined below), the Company issued investors Warrants (as defined below) to purchase 8,750,000 shares of Common Stock, with an exercise price of $4.00 per share (subject to adjustment), for a period of five years from the date of issuance. For more information on the Private Placement, see “Note 12 – Preferred Stock”.

 

The Warrants were determined to be within the scope of ASC 480-10 as they are puttable to the Company at Holders’ election upon the occurrence of a Fundamental Transaction (as defined in the agreements). As such, the Company recorded the Warrants as a liability at fair value with subsequent changes in fair value recognized in earnings. The Company utilized the Black-Scholes-Merton Model to calculate the value of the Warrants issued on May 10, 2023. The fair value of the Warrants of approximately $14,127,000 was estimated at the date of issuance using the fair value of our common stock of $2.74 on the issuance date and was based on the following weighted average assumptions: dividend yield 0%; expected term of 5.0 years; equity volatility of 80.0%; and a risk-free interest rate of 3.37%.

 

Transaction costs incurred attributable to the issuance of the Warrants of approximately $913,640 were immediately expensed in accordance with ASC 480 and is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations.

 

During the three months ended July 31, 2024, the Company recorded a gain of approximately $2,084,000 related to the change in fair value of the warrant liability which is recorded in other income (expense) on the Condensed Consolidated Statements of Operations. The fair value of the Warrants of $8,700,000 was estimated at July 31, 2024, utilizing the Black-Scholes-Merton Model using the fair value of our common stock of $1.96 and the following weighted average assumptions: dividend yield 0%; remaining term of 3.78 years; equity volatility of 90.0%; and a risk-free interest rate of 4.05%.

 

A summary of the Company’s warrant activity and related information for the three months ended July 31, 2024, are shown below:

               
    Warrants    

Weighted
Average
Exercise Price

Per Share

 
Outstanding, April 30, 2024     18,570,847     $ 4.54  
Issued            
Exercised            
Expired            
Outstanding, July 31, 2024     18,570,847       4.54  
Exercisable, July 31, 2024     18,570,847     $ 4.54